Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe

Value in Health

Volumn 2, Issue 5, 1999, Pages 323-332

  Drummond, Michael ^a   Dubois, Dominique ^b   Garattini, Livio ^c   Horisberger, Bruno ^d   Jönsson, Bengt ^e   Kristiansen, Ivar Sönbö ^f   Le Pen, Claude ^g   Pinto, Carlos Gouveia ^h   Poulsen, Peter Bo ^f   Rovira, Joan ⁱ   Rutten, Frans ^j   Von der Schulenburg, Matthias Graf ^k   Sintonen, Harri ^l  

^a UNIVERSITY OF YORK   (United Kingdom)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Health Management Research Institute   (Switzerland)

^e STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^g UNIVERSITÉ PARIS DAUPHINE   (France)

^h UNIVERSITY OF LISBON   (Portugal)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^k LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^l UNIVERSITY OF EASTERN FINLAND   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001245197     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.1999.25003.x     Document Type: Article

References (11)

1. OHE-IFPMA. Health Economic Evaluation Database (HEED). London: Office for Health Economics, 1999.
2. Drummond MF, Rutten FFH, Brenna A, et al. Economic evaluation of pharmaceuticals: a European perspective. Pharmacoeconomics 1993;4:173-86.
3. Drummond ME, Jönsson B, Rutten FFH. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997;40:199-215.
4. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes (2nd ed.). Oxford: Oxford University Press, 1997.
5. Elsinga E, Rutten FEH. Economic evaluation in support of national health policy: the case of The Netherlands. Soc Sci Med 1997;45:607-20.
6. Le Pen C. Pharmaceutical economy and the economic assessment of drugs in France. Soc Sci Med 1997;45:637-43.
7. Badia X, Segú JL, Garcia F, et al. Análisis costeeficacia des tratamiento con anticuerpos monoclonales antiendotoxina en la sepsis por gram negativos. Revista Med Clinica 1993;100:84-9.
8. Drummond MF. Evidence-based medicine and cost-effectiveness: uneasy bedfellows? Evidence-Based Med 1998;3:133.
9. Poulsen P, Christiansen T, Alban A, et al. Model for health economic analysis - urine infections of children. In: Model for a Clinical Practice Programme (Reference Programme) Health Economic Appendix National Board of Health, Copenhagen, 1992.
10. Eccles M, Freemantle N, Mason J, et al. North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. Br Med J 1998;316:1369-75.
11. Mason JM, Eccles M, Freemantle N, et al. A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines. Health Policy 1999;47:37-52.